Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 445 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: heparin Clear all
Withdrawn Not applicable Interventional

Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department

NCT00657228
View directory record Official record
Conditions
Anaphylaxis
Interventions
Intravenous heparin, Saline
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 23, 2026, 9:56 AM EDT
Active, not recruiting Not applicable Interventional

Blood Purification for the Treatment of Pathogen Associated Shock

NCT05011656
View directory record Official record
Conditions
Septic Shock
Interventions
Seraph-100 + State of the Art Care, State of the Art Care
Device
Lead sponsor
ExThera Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Brunswick, Georgia • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 23, 2026, 9:56 AM EDT
Terminated Phase 3 Interventional Results available

Clot Dissolving Treatment for Blood Clots in the Lungs

NCT00680628
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Tenecteplase + Enoxaparin, 0.9% Saline + Enoxaparin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
7
States / cities
Sacramento, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 23, 2026, 9:56 AM EDT
Completed Not applicable Interventional Results available

Study Comparing Synthetic Vascular Grafts in Patients With Peripheral Artery Disease (PAD) Who Require Artery Bypass.

NCT01113892
View directory record Official record
Conditions
Peripheral Arterial Occlusive Disease
Interventions
vascular grafts
Device
Lead sponsor
Maquet Cardiovascular
Industry
Eligibility
21 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Oct 23, 2026, 9:56 AM EDT
Completed Phase 2 Interventional

A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome

NCT00932100
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS)
Interventions
REG1, Heparin
Drug
Lead sponsor
Regado Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
26
States / cities
Huntsville, Alabama • Sacramento, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2012 · Synced Oct 23, 2026, 9:56 AM EDT
Recruiting Not applicable Interventional

Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)

NCT03728166
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Electronic alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 9:56 AM EDT
Withdrawn Phase 2 Interventional

A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia

NCT01048177
View directory record Official record
Conditions
Vulvodynia
Interventions
Bladder instillation with heparin/ lidocaine
Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 23, 2026, 9:56 AM EDT
Recruiting Phase 2 Interventional

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428
View directory record Official record
Conditions
Carcinoma, Non-small-Cell Lung
Interventions
Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
La Jolla, California • Orange, California • Stanford, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 9:56 AM EDT
Terminated Not applicable Interventional Results available

The GORE Viabahn Endoprosthesis for the Treatment of Venous Occlusions and Stenoses

NCT01406795
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Gore Viabahn Heparin Coated Stent
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 23, 2026, 9:56 AM EDT
Completed Phase 2 Interventional

The Female Microbiome in Patients Undergoing Bladder Instillation Therapy

NCT05414305
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome, Microbial Colonization
Interventions
Heparin & Alkalinized Lidocaine Bladder Instillation
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 23, 2026, 9:56 AM EDT
Completed Phase 3 Interventional Results available

PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot

NCT01274637
View directory record Official record
Conditions
Venous Thromboembolism, Postpartum
Interventions
Dalteparin Sodium
Drug
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Charlottesville, Virginia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 23, 2026, 9:56 AM EDT
Completed Not applicable Interventional Results available

Dalteparin in Preventing DVT in Participants With Cancer

NCT00525057
View directory record Official record
Conditions
Bone Sarcoma, Femur Fracture, Lymphoma, Metastatic Neoplasm, Pathologic Fracture, Plasma Cell Myeloma, Soft Tissue Sarcoma
Interventions
Dalteparin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 23, 2026, 9:56 AM EDT
Recruiting Phase 4 Interventional

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

NCT07189897
View directory record Official record
Conditions
Venous Thromboembolism, Head and Neck Cancer
Interventions
Enoxaparin, Apixaban
Drug
Lead sponsor
Kiranya Arnold
Other
Eligibility
18 Years to 89 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 23, 2026, 9:56 AM EDT
Completed Phase 4 Interventional

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

NCT01828697
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Low dose nadroparin, Intermediate dose nadroparin, Low dose enoxaparin, Intermediate dose enoxaparin, Low dose dalteparin, Intermediate dose dalteparin, Fixed low dose tinzaparin, Intermediate dose tinzaparin
Drug
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 23, 2026, 9:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of UC-MSCs for COVID-19 Patients

NCT04355728
View directory record Official record
Conditions
Corona Virus Infection, ARDS, ARDS, Human, Acute Respiratory Distress Syndrome, COVID-19
Interventions
Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care., Vehicle + Heparin along with best supportive care
Biological · Other
Lead sponsor
Camillo Ricordi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 23, 2026, 9:56 AM EDT
Terminated Phase 2 Interventional Results available

Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

NCT02591199
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
URG101, Placebo, Lidocaine, Heparin
Drug
Lead sponsor
Urigen
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Escondido, California • San Diego, California • Cartersville, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 23, 2026, 9:56 AM EDT
Terminated Phase 4 Interventional Results available

Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery

NCT01547728
View directory record Official record
Conditions
Thrombophilia Due to Acquired Antithrombin III Deficiency
Interventions
Recombinant antithrombin (rhAT)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Oct 23, 2026, 9:56 AM EDT
Completed Phase 3 Interventional Results available

Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

NCT00371683
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin + Placebo, Apixaban + Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
3,608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
25
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 23, 2026, 9:56 AM EDT
Completed Phase 2 Interventional

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

NCT00306254
View directory record Official record
Conditions
Venous Thrombosis
Interventions
PD 0348292, Enoxaparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
58
States / cities
Birmingham, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2007 · Synced Oct 23, 2026, 9:56 AM EDT
Completed Early Phase 1 Interventional

Recurrent Urinary Tract Infections and Heparin (RUTIH Trial)

NCT02246270
View directory record Official record
Conditions
Recurrent Urinary Tract Infections
Interventions
Intravesical Heparin, Placebo
Drug · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 23, 2026, 9:56 AM EDT
Completed Phase 3 Interventional Results available

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

NCT01583218
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Betrixaban, Enoxaparin
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
7,513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
75
States / cities
Birmingham, Alabama • Bakersfield, California • Fresno, California + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 23, 2026, 9:56 AM EDT
Completed Phase 1 Interventional

Treatment for Blood Clots in the Veins of the Legs

NCT00001713
View directory record Official record
Conditions
Embolism, Thrombophlebitis
Interventions
Recombinant Tissue Plasminogen Activator, Heparin, Warfarin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 9:56 AM EDT
Completed No phase listed Observational Results available

Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study

NCT01178333
View directory record Official record
Conditions
Heparin Induced Thrombocytopenia
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
Not listed
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
21
States / cities
Iowa City, Iowa • New Orleans, Louisiana • Baltimore, Maryland + 12 more
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Oct 23, 2026, 9:56 AM EDT
Terminated Phase 2 Interventional Results available

Nebulized Heparin for COVID19-associated Acute Respiratory Failure

NCT04842292
View directory record Official record
Conditions
Covid19
Interventions
Heparin, Placebo
Drug
Lead sponsor
Brittany Bissell
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 23, 2026, 9:56 AM EDT